Table 1.
Demographics and baseline clinical characteristics of all study participants.
Table 2.
Demographics and baseline clinical characteristics of DME patients.
Table 3.
Variables associated with the preoperative CST of DME patients as revealed by regression analyses.
Table 4.
Results of logistic regression, effect on responsiveness to IVB.
Fig 1.
Box-and-whisker plots for central subfield thickness (CST), best-corrected visual acuity (BCVA), and intraocular pressure (IOP) changes in patients receiving dexamethasone implants due to poor responsiveness to 3 months of intravitreal bevacizumab (IVB) injections.
The circles represent outliers. (A) CST was significantly reduced both after IVB injection and placement of dexamethasone implants. (B) BCVA did not improve significantly after IVB injection, but did upon dexamethasone treatment. (C) The baseline IOP was 15.52 ± 3.23 mmHg, and increased significantly to 16.61 ± 2.21 mmHg after placement of dexamethasone implants.